DE2641556A1 - 4-trifluormethylbenzoesaeurederivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen - Google Patents
4-trifluormethylbenzoesaeurederivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungenInfo
- Publication number
- DE2641556A1 DE2641556A1 DE19762641556 DE2641556A DE2641556A1 DE 2641556 A1 DE2641556 A1 DE 2641556A1 DE 19762641556 DE19762641556 DE 19762641556 DE 2641556 A DE2641556 A DE 2641556A DE 2641556 A1 DE2641556 A1 DE 2641556A1
- Authority
- DE
- Germany
- Prior art keywords
- acid
- trifluoromethylbenzoic acid
- hydroxy
- agent
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 22
- 230000008569 process Effects 0.000 title claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- 239000002253 acid Substances 0.000 title description 11
- 238000004519 manufacturing process Methods 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims description 25
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 16
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- XMLFPUBZFSJWCN-UHFFFAOYSA-N 2-Hydroxy-4-trifluoromethyl benzoic acid Chemical compound OC(=O)C1=CC=C(C(F)(F)F)C=C1O XMLFPUBZFSJWCN-UHFFFAOYSA-N 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- CCGKOQOJPYTBIH-UHFFFAOYSA-N ethenone Chemical compound C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 7
- 239000012345 acetylating agent Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 5
- 239000008298 dragée Substances 0.000 claims description 5
- 239000006188 syrup Substances 0.000 claims description 5
- 235000020357 syrup Nutrition 0.000 claims description 5
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 claims description 4
- 239000012346 acetyl chloride Substances 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 239000000829 suppository Substances 0.000 claims description 4
- UGEJOEBBMPOJMT-UHFFFAOYSA-N 3-(trifluoromethyl)phenol Chemical compound OC1=CC=CC(C(F)(F)F)=C1 UGEJOEBBMPOJMT-UHFFFAOYSA-N 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 150000008064 anhydrides Chemical class 0.000 claims description 3
- 239000006227 byproduct Substances 0.000 claims description 3
- 239000001569 carbon dioxide Substances 0.000 claims description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 239000012442 inert solvent Substances 0.000 claims description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 3
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 claims description 3
- 239000007795 chemical reaction product Substances 0.000 claims description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 2
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 150000007530 organic bases Chemical class 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 claims 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 claims 1
- 150000007522 mineralic acids Chemical class 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- RMWVZGDJPAKBDE-UHFFFAOYSA-N 2-acetyloxy-4-(trifluoromethyl)benzoic acid Chemical compound CC(=O)OC1=CC(C(F)(F)F)=CC=C1C(O)=O RMWVZGDJPAKBDE-UHFFFAOYSA-N 0.000 description 15
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 15
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 13
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- 229930182837 (R)-adrenaline Natural products 0.000 description 11
- 229960005139 epinephrine Drugs 0.000 description 11
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 10
- 102000008186 Collagen Human genes 0.000 description 10
- 108010035532 Collagen Proteins 0.000 description 10
- 229920001436 collagen Polymers 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000001772 blood platelet Anatomy 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- 238000004220 aggregation Methods 0.000 description 6
- 230000002776 aggregation Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 230000015271 coagulation Effects 0.000 description 5
- 238000005345 coagulation Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000020764 fibrinolysis Effects 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 108010094028 Prothrombin Proteins 0.000 description 4
- 102100027378 Prothrombin Human genes 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 230000023555 blood coagulation Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000003480 fibrinolytic effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 229940039716 prothrombin Drugs 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- LKPFWCPZERQLFI-UHFFFAOYSA-N 2,4,6-trimethylpyridine;hydrochloride Chemical compound Cl.CC1=CC(C)=NC(C)=C1 LKPFWCPZERQLFI-UHFFFAOYSA-N 0.000 description 3
- FXPYSJWVFOTNAN-UHFFFAOYSA-N 2-phosphono-4-(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC=C(C(F)(F)F)C=C1P(O)(O)=O FXPYSJWVFOTNAN-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- -1 Chlorine ions Chemical class 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000001435 Thromboembolism Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- BWZVCCNYKMEVEX-UHFFFAOYSA-N 2,4,6-Trimethylpyridine Chemical compound CC1=CC(C)=NC(C)=C1 BWZVCCNYKMEVEX-UHFFFAOYSA-N 0.000 description 2
- SWKPKONEIZGROQ-UHFFFAOYSA-N 4-trifluoromethylbenzoic acid Chemical class OC(=O)C1=CC=C(C(F)(F)F)C=C1 SWKPKONEIZGROQ-UHFFFAOYSA-N 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- 241000287531 Psittacidae Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical class O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- ZWLPBLYKEWSWPD-UHFFFAOYSA-N o-toluic acid Chemical compound CC1=CC=CC=C1C(O)=O ZWLPBLYKEWSWPD-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000009424 thromboembolic effect Effects 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- FBRJYBGLCHWYOE-UHFFFAOYSA-N 2-(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(F)(F)F FBRJYBGLCHWYOE-UHFFFAOYSA-N 0.000 description 1
- FFKUDWZICMJVPA-UHFFFAOYSA-N 2-phosphonooxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OP(O)(O)=O FFKUDWZICMJVPA-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920003136 Eudragit® L polymer Polymers 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000007065 Kolbe-Schmitt synthesis reaction Methods 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- ASBZEHIUZOLBIX-UHFFFAOYSA-N acetyl 2-acetyloxy-4-(trifluoromethyl)benzoate Chemical compound CC(=O)OC(=O)C1=CC=C(C(F)(F)F)C=C1OC(C)=O ASBZEHIUZOLBIX-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 229910021417 amorphous silicon Inorganic materials 0.000 description 1
- 229910021486 amorphous silicon dioxide Inorganic materials 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 230000000001 effect on platelet aggregation Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229950010892 fosfosal Drugs 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 229940127216 oral anticoagulant drug Drugs 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/15—Preparation of carboxylic acids or their salts, halides or anhydrides by reaction of organic compounds with carbon dioxide, e.g. Kolbe-Schmitt synthesis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Description
richtungen hergestellt werden.
I | Aggregationsmitt el (Plasmakonzentra-I tion) ■ ; |
2 - Hydroxyderivat | IBA C%) | 2-Acetoxyderivat | IBA- C%) | i 2-Phosphonoxyderivat | IBA C%) |
ADP -6 > 4.1x10 M > > > » . r )! |
, PC (molar)* |
00 O) I I I
(O O.I I I I I I to to ι ι ι |
PC (molar)* |
26.0
37.5 51.9 93.7 |
PC (molar)* |
11.2
23.1 57.5 69.8 |
|
C
U O O IV. "«* C σ Io « |
U ... ... ,
► Epinephrin ** ! |
0.83xl0"3
2.08X10"3 4.15X10"3 6.25X10"3 8.3OxIO"3 |
0.83xl0"3
2.08X10"3 . 4.15X10"3 6.25xlO"3 8.3OxIO"3 |
0.83xl0"3
2.08xl0"3 4.15X10"3 ·. 6.25xlO~3 8.3OxIO"3 |
|||
■ | Kollagen i j 33.3^ug/ml |
27.2 48.3 |
34.5 52.7 |
45.5 94.5 |
|||
4.15X10"3
8.3OxIO"3 |
4.15X10"3
8.3OxIO"3 |
4.15X10"3
8.3OxIO"3 |
Aggregationsmittel und seine Konzen tration im Plasma |
2-Hydroxyderivat ; | IBA (%)* | 2-Acetoxyderivat ; | ΪΒΑ (%)* | 2-Phosphonoxyderivat · | 56.6 60.8 |
ADP -6 1.6x10 M |
PC (molar) | 70.0 100.0 |
PC (molar) | 22.5 33.6 |
PC (molar) | 59.0 |
CO OO cn »^Epinephrin · ^ -6 £JL.4xlO M to. |
6.25X10"3 8.3OxIO"3 |
32.0 , 91.0 |
.6.25x10"3 8.3OxIO""3 |
74.0 | 6.25xlO"3 8.3OxIO"3 |
0.0 12.6 T |
Kollagen 33.3 mcg/ml |
3.3OxIO-3 8.1OxIO"3 |
58.0 75.0 |
17.0X10"3 | 37.5 62.0 |
17.OxIO"3 | |
8.3OxIO"3 17.OxIO-3 |
4.10.10"3 8.3OxIO-3 |
4.1OxIO"3 8.3OxIO"3 |
||||
und Kollagen bewirkte Aggregation von menschlichen Blutplättchen in vitro.
Biol. Med. 137: 662, 1971) berechnet.
Menschen | β> | (CS.) | Kontrolle | ADP (yuM) ' | 7- Tag | Epinephrin (.AM) | 4. Tag | .7» Tag | |
.— a I O |
:cd ς | (A.S.) | 0.50 | 4. Tag | 2.50 | Kontrolle | 1.25 | ||
•rl N
rl C •P CL |
1 2 | (T.D.) | 0.50 | . 1.25' | 0.25 | 0.25 | 0.25 | ||
3 | 1 | (J.M.) | 0.50· | 2..5Ό · ' | 2.50 | 0..25 | . 1.25 · | 12.5 | |
ο α •P E |
2
, 3 |
(A.M.) | >1.25 | 2.50 | 2.50 | 1.25 . | 12.5 | 1.25 | |
Φ ί-
Ο C |
4 | 2.50 | >2.50 | 2.50 · | 1.25 | 1.25 | 1.25 | ||
CMV1 I • I I |
(J.J.P.) | >2..5O | 1.25 | ||||||
rl I |
H
^* ο •CÖ CQ |
(M.V.)
(CT.) |
2.50 | 1.25 | 1.25 | 1.25 | |||
(Π. P..) | 2.50 ·· 2.50 |
2.50 | 1.25 1.25 |
12.5 | , 1.25 12.5 |
• 0.25 1.25· |
|||
M | (A.A.) | 1.25 | 1.25 2.50 |
1.25 | 1.25 >125 |
0.25 | 0.25 | ||
ft C | (M.P.) | 1.25 | 1.25 | 1.25 | 1.25 | 1.25 | 1.25 | ||
co ε O t |
• 2.50 | 2.50 | 1.25 | 1.25 | 125 | 12.5 | |||
OJV | >2.50 | ' 1.25 | |||||||
Menschen | • | 29 | Kollagen (33,3 | 4. | yug/m) | y (mm) |
Verzöger, (xc) |
7- Tag | • | 13 | y (mm). |
|
ι S- | 1.(CS.) | 22 | Verzöger., (xc) |
Tag | __ | 108 | κ (mm) |
14 | 24 | |||
■d" -P Q> ι ω p-i |
2 (A. S.) | Kontrolle | 13 . 22 |
y (mm) |
__ | X (mm) |
41 | 60 | 36 | . 15 | 58 | |
Oi etoxy luorm oesäu |
3 (T.D.) 4 (J.M.) |
Verzögerung κ (xc) (nun) |
• 61 | 73 | 60 | __ | 41 ' 41 |
96 72 |
13 | 23 | 46 37 |
|
O Ή Ν | 5 (A.M.) | 36 | 51 | 72 ■ 60 |
22 | 45 | 84 | 31 ' 16 |
12 | 33 | ||
tr|(vi -ρ ,0 | 30 | 33 63 |
72 | 24 17 |
22 | 13 | ||||||
48 24 |
23 | 54 | 25 | |||||||||
S4 ι | 1 (J.J.P.) | 36 | 18 | 49 | 48 | 53 | ||||||
2 (M.V.) | . 20 | 3S | 42 | 24 | 38 | |||||||
Pl ω (4 O Ef 3 |
3 (CT.) | 22 | . 44 | 24 | 14 | , 36 | . 48 | 36 | ||||
Λ h:cö ft O CQ |
4 (R.P.) | 48 | 20 | 50 | 48 | 16 | 36 | 36 ' | 26 | |||
CQ pi φ
OHO Λ Ή Ν |
5 (A.A.) | 36 | 27 | 45 | 24 | 17 | 37 ! | 36 | 4S | |||
M ι #_J e-4 OJ +5 ,Q |
6 (M.P.) | 60 | 50 | 36 | 22 | 41 | 36 | 48 | ||||
24 | 66 | 48 | 18 | |||||||||
24 | 35 | 17 | ||||||||||
84 | ||||||||||||
(0 Tage)
positiv bei vier Menschen
196,6+19,6 145,1+9,3
negativ
42,9+0,5 42,0+1,0 45,0+1,4
Suppositorien:
Claims (16)
- Patentansprüche { 1 y Verbindung der Pormelworin R Wasserstoff oder eine Acylgruppe ist, die sich von einer organischen oder anorganischen Säure ableitet sowie deren pharmazeutisch brauchbare Salze.
- 2. Verbindung nach Anspruch 1, worin R = Wasserstoff.
- 3. Verbindung nach Anspruch 1, worin R = Acetyl.
- 4. Verbindung nach Anspruch 1, worin R = Phosphono mit der FormelCOOH)PO(OH)
- 5. Verfahren zur Herstellung der Verbindung gemäß Anspruch 2, dadurch gekennzeichnet, daß man m-Trifluormethylphenol mit einem Carboxylierungsmittel bei erhöhter Temperatur und erhöhtem Druck behandelt und das Reaktionsprodukt ausfällt.
- 6. Verfahren gemäß Anspruch 5» dadurch gekennzeichnet, daß man als Garboxylxerungsmittel Kaliumcarbonat und Kohlendioxid verwendet.
- 7- Verfahren zur Herstellung von 2-Acetoxy-4-trifluormethylben-709852/0629Λ-zoesäure gemäß Ansprucli 1 oder 3» dadurch gekennzeichnet, daß man 2-Hydroxy-4—trifluormethylbenzoesäure, erhalten nach dem Verfahren gemäß Anspruch 5» mit einem Acetylierungsmittel umsetzt.
- 8· Verfahren gemäß Anspruch 7» dadurch gekennzeichnet, daß man als Acetylierungsmittel Essigsäureanhydrid verwendet und die Umsetzung in Anwesenheit eines Katalysators vornimmt.
- 9. Verfahren gemäß Anspruch 8, dadurch gekennzeichnet, daß man als Katalysator Schwefelsäure verwendet.
- 10. Verfahren gemäß Anspruch 7» dadurch gekennzeichnet, daß man als Acetylierungsmittel Acetylchlorid verwendet und die Reaktion in Anwesenheit eines inerten Lösungsmittels und einer organischen Base durchführt, die dazu geeignet ist, den als Reaktionsnebenprodukt gebildeten Chlorwasserstoff zu binden.
- 11. Verfahren gemäß Anspruch 10, dadurch gekennzeichnet, daß man als Lösungsmittel Ithyläther und als organische Base Collidin verwendet.
- 12. Verfahren gemäß Anspruch 7» dadurch gekennzeichnet, daß man als Acetylierungsmittel Keten verwendet und das bei der Reaktion mit dem Keten gebildete gemischte Anhydrid mit Wasser hydrolysiert.
- 13· Verfahren zur Herstellung von 2-Ehosphonoxy-4~trifluormethylbenzoesäure, dadurch gekennzeichnet, daß man die beim Verfahren von Anspruch 5 erhaltene 2-Hydroxy-4-trifluormethylbenzoesäure mit einem Phosphonierungsmittel umsetzt.709862/0620-χ-
- 14·. Verfahren gemäß Anspruch 13, dadurch gekennzeichnet, daß man als Phosphonierungsmittel Phosphorpentachlorid verwendet.
- 15· Pharmazeutische Zusammensetzung, enthaltend zumindest eine der Verbindungen gemäß Anspruch 1 als wirksamen Bestandteil gegebenenfalls mit einem Träger und gegebenenfalls mit üblichen Hilfsstoffen.
- 16. Zusammensetzung gemäß Anspruch 15 in Form von Kapseln, Tabletten, Dragees oder Suppositorien mit einem Gehalt von 200 bis 300 mg der Wirksubstanz pro Einheit.17· Zusammensetzung gemäß Anspruch 15 in Form eines Sirups mit einem Gehalt von etwa 4- bis 5 6 des wirksamen Bestandteils pro 100 ml.709852/0629
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US05/694,523 US4096252A (en) | 1976-06-10 | 1976-06-10 | 4-Trifluoromethylbenzoic acid derivatives as thromboembolic agents |
Publications (2)
Publication Number | Publication Date |
---|---|
DE2641556A1 true DE2641556A1 (de) | 1977-12-29 |
DE2641556C2 DE2641556C2 (de) | 1988-12-29 |
Family
ID=24789174
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE2661085A Expired DE2661085C2 (de) | 1976-06-10 | 1976-09-15 | |
DE19762641556 Granted DE2641556A1 (de) | 1976-06-10 | 1976-09-15 | 4-trifluormethylbenzoesaeurederivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE2661085A Expired DE2661085C2 (de) | 1976-06-10 | 1976-09-15 |
Country Status (15)
Country | Link |
---|---|
US (2) | US4096252A (de) |
JP (1) | JPS5914007B2 (de) |
AU (3) | AU2588077A (de) |
BE (1) | BE855588A (de) |
CA (1) | CA1090705A (de) |
DE (2) | DE2661085C2 (de) |
ES (1) | ES459855A1 (de) |
FI (1) | FI771842A (de) |
FR (1) | FR2354335A1 (de) |
GB (1) | GB1588633A (de) |
GR (1) | GR63213B (de) |
IE (1) | IE45962B1 (de) |
NL (1) | NL7706433A (de) |
PT (1) | PT66637B (de) |
ZA (1) | ZA773459B (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0491326A2 (de) * | 1990-12-17 | 1992-06-24 | ISTITUTO GUIDO DONEGANI S.p.A. | Verfahren zur Funktionalisierung von Trifluormethylbenzolen |
CN1308282C (zh) * | 2005-01-11 | 2007-04-04 | 山东师范大学 | 一种4-三氟甲基乙酰水杨酸的催化合成方法 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4397790A (en) * | 1980-12-03 | 1983-08-09 | Monsanto Company | Isophosphinolinone derivatives |
DE3127237A1 (de) * | 1981-07-10 | 1983-01-20 | Hoechst Ag, 6000 Frankfurt | Magenvertraegliche arzneiformen von xanthinderivaten und verfahren zu ihrer herstellung |
US4766389A (en) * | 1986-09-03 | 1988-08-23 | Extrude Hone Corporation | Capacitor array sensors tactile and proximity sensing and methods of use thereof |
GB8927503D0 (en) * | 1989-12-04 | 1990-02-07 | Kronem Systems Inc | Enzyme-amplified lanthanide chelate luminescence |
ES2136581B1 (es) | 1998-05-27 | 2000-09-16 | Uriach & Cia Sa J | Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb. |
US6509377B1 (en) * | 1999-05-26 | 2003-01-21 | J. Uriach & Cia, S.A. | Use of a 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitors of the activation of the nuclear transcription factor NF-κB |
ES2154242B1 (es) * | 1999-09-03 | 2001-10-16 | Uriach & Cia Sa J | Nuevos sistemas polimericos biocompatibles portadores de triflusal o htb. |
ES2190373B1 (es) * | 2001-12-07 | 2004-10-16 | J. URIACH & CIA, S.A. | Uso del acido 2-hidroxi- o 2-acetiloxi-4-trifluorometilbenzoico como agente para el tratamiento y prevencion del deterioro cognitivo ligero. |
KR100503267B1 (ko) * | 2002-09-17 | 2005-07-22 | (주)리드젠 | 2-아세틸옥시-4-트리플루오로메틸 벤조산의 제조 방법 |
WO2009100534A1 (en) * | 2008-02-14 | 2009-08-20 | Kardiatech, Inc. | Combination therapy to treat vascular disorders |
US20100069326A1 (en) * | 2008-02-14 | 2010-03-18 | Wasimul Haque | Combination Therapies to Treat Cardio- and Cerebro-Vascular Disorders |
CN101695496A (zh) * | 2009-10-15 | 2010-04-21 | 苏春华 | 一种含有三氟柳和氯吡格雷的药物组合物 |
ES2389348B1 (es) | 2011-04-05 | 2013-09-23 | Simbec Ibérica Sl | Polvo compuesto de triflusal, uso del mismo para granulados, comprimidos o sobres, procedimiento para la preparación de dicho polvo compuesto y uso de una o mas ciclodextrinas para estabilizar el triflusal. |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2213607A1 (de) * | 1972-03-21 | 1973-09-27 | Hoechst Ag | Trifluormethyl-salicylanilide und verfahren zu ihrer herstellung |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE25085E (en) * | 1961-11-21 | Therapeutic use of ortho-carboxy-sub | ||
CA621838A (en) * | 1961-06-13 | E. Fancher Otis | Salts of phosphosalicylic acid | |
FR1174923A (fr) * | 1956-05-10 | 1959-03-18 | Ciba Geigy | Procédé de préparation de dérivés phosphorylés d'acides organiques hydroxylés |
US3019253A (en) * | 1958-05-15 | 1962-01-30 | Pennsalt Chemicals Corp | Acetyl-4-trifluoromethyl salicylic acid |
-
1976
- 1976-06-10 US US05/694,523 patent/US4096252A/en not_active Expired - Lifetime
- 1976-09-15 DE DE2661085A patent/DE2661085C2/de not_active Expired
- 1976-09-15 DE DE19762641556 patent/DE2641556A1/de active Granted
- 1976-12-30 US US05/755,851 patent/US4110442A/en not_active Expired - Lifetime
-
1977
- 1977-06-01 GR GR53603A patent/GR63213B/el unknown
- 1977-06-03 CA CA279,838A patent/CA1090705A/en not_active Expired
- 1977-06-06 PT PT66637A patent/PT66637B/pt unknown
- 1977-06-07 ES ES459855A patent/ES459855A1/es not_active Expired
- 1977-06-07 AU AU25880/77A patent/AU2588077A/en not_active Expired - Fee Related
- 1977-06-08 ZA ZA00773459A patent/ZA773459B/xx unknown
- 1977-06-09 FR FR7717707A patent/FR2354335A1/fr active Granted
- 1977-06-10 GB GB24415/77A patent/GB1588633A/en not_active Expired
- 1977-06-10 FI FI771842A patent/FI771842A/fi not_active Application Discontinuation
- 1977-06-10 IE IE1197/77A patent/IE45962B1/en not_active IP Right Cessation
- 1977-06-10 BE BE178361A patent/BE855588A/xx not_active IP Right Cessation
- 1977-06-10 JP JP52068731A patent/JPS5914007B2/ja not_active Expired
- 1977-06-10 NL NL7706433A patent/NL7706433A/xx not_active Application Discontinuation
-
1986
- 1986-02-27 AU AU54156/86A patent/AU5415686A/en not_active Abandoned
-
1988
- 1988-12-22 AU AU27477/88A patent/AU2747788A/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2213607A1 (de) * | 1972-03-21 | 1973-09-27 | Hoechst Ag | Trifluormethyl-salicylanilide und verfahren zu ihrer herstellung |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0491326A2 (de) * | 1990-12-17 | 1992-06-24 | ISTITUTO GUIDO DONEGANI S.p.A. | Verfahren zur Funktionalisierung von Trifluormethylbenzolen |
EP0491326A3 (en) * | 1990-12-17 | 1992-11-04 | Istituto Guido Donegani S.P.A. | Process for the functionalization of trifluoromethylbenzenes |
CN1308282C (zh) * | 2005-01-11 | 2007-04-04 | 山东师范大学 | 一种4-三氟甲基乙酰水杨酸的催化合成方法 |
Also Published As
Publication number | Publication date |
---|---|
US4096252A (en) | 1978-06-20 |
JPS5914007B2 (ja) | 1984-04-02 |
PT66637B (en) | 1978-11-09 |
FR2354335B1 (de) | 1982-11-12 |
GB1588633A (en) | 1981-04-29 |
ES459855A1 (es) | 1978-04-01 |
GR63213B (en) | 1979-10-09 |
DE2661085C2 (de) | 1988-04-07 |
NL7706433A (nl) | 1977-12-13 |
DE2641556C2 (de) | 1988-12-29 |
AU2747788A (en) | 1989-04-27 |
US4110442A (en) | 1978-08-29 |
IE45962L (en) | 1977-12-10 |
ZA773459B (en) | 1978-05-30 |
AU5415686A (en) | 1986-07-31 |
JPS52156831A (en) | 1977-12-27 |
PT66637A (en) | 1977-07-01 |
CA1090705A (en) | 1980-12-02 |
AU2588077A (en) | 1978-12-14 |
FR2354335A1 (fr) | 1978-01-06 |
FI771842A (de) | 1977-12-11 |
BE855588A (fr) | 1977-10-03 |
IE45962B1 (en) | 1983-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2641556A1 (de) | 4-trifluormethylbenzoesaeurederivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen | |
DE2833898C2 (de) | ||
EP0149242B1 (de) | 1-(2-Hydroxyaryl)-alkan-1-on-oxime, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln | |
DE2549783B2 (de) | Triglyceride mit entzündungshemmender Wirkung | |
FIESER et al. | Naphthoquinone antimalarials: XVIII. Metabolic oxidation products | |
DE3116067A1 (de) | Therapeutische zusammensetzungen mit schmerzstillenden und entzuendungshemmenden eigenschaften, die als wirkstoffe adenosinderivate enthalten | |
DE2723051A1 (de) | N-(acyl)-p-amino-n'-(monosubstit.)- benzamide sowie diese enthaltende arzneimittel | |
DE2342460A1 (de) | Eisen- oder aluminiumglycyrrhizinat enthaltendes produkt, verfahren zu seiner herstellung und dieses produkt enthaltendes arzneimittel | |
DE1806926A1 (de) | Lithiumsalz der Hydrochinonsulfonsaeure | |
DE2351292C3 (de) | 2,10-Dichlor-6-äthoxycarbonyl-12-methyl-12H-dibenzo[d,g][1,3]dioxocin und Verfahren zu dessen Herstellung sowie diese Verbindung enthaltende Arzneimittel | |
US3787580A (en) | 2-(6'-methoxy-2'-naphthyl)propionic acid and -1-propanol derivatives having anti-inflammatory,analgesic and anti-pyretic activities | |
DE2038836C3 (de) | Arzneimittel | |
DE69323998T2 (de) | Pharmazeutisch aktive flavilium verbindungen | |
DE2029807C3 (de) | 4-Aminomethylbicyclo- [2.2.2] -octyl-(l)-essigsäure und ihre physiologisch verträglichen Salze, Verfahren zu ihrer Herstellung und deren Verwendung | |
US2641609A (en) | Therapeutic compound and method of preparing the same | |
US4207339A (en) | Anti-ulcer pharmaceutical composition containing inositol hexasulfate or an alkaline metal salt thereof as active ingredient | |
CN110684066B (zh) | 胞二磷胆碱药物制剂及其脑梗塞急性期意识障碍的新用途 | |
DE2407016B2 (de) | 2-Alkoxybenzoylaminocarbonsäuren, Verfahren zu deren Herstellung und diese Verbindungen enthaltende antipyretische Mittel | |
DE2244461C3 (de) | 3-Chlor-4,4'-disulfoxydiphenyl-(2-pvridyl)-methansalze, Verfahren zu deren Herstellung sowie diese Salze enthaltende pharmazeutische Zusammensetzungen | |
DE3427618A1 (de) | Homocarnosin und seine salze zur anwendung als therapeutische wirkstoffe | |
DE914854C (de) | Verfahren zur Herstellung von Thiosemicarbazonen | |
DE1543733B2 (de) | Aluminium-bis-alpha-ip-chlorphenoxy) isobutyrat und diese Verbindung als Wirkstoffenthaltende Heilmittel | |
AT235473B (de) | Verfahren zur Herstellung von 7-Dehydro-cholesterinestern | |
CH644594A5 (en) | 4-Acetamidophenyl alpha-(2-methyl-ind-[en/ol]-3-yl)acetates | |
DE19824123A1 (de) | Gallensäurederivat, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
OC | Search report available | ||
8141 | Disposal/no request for examination | ||
8110 | Request for examination paragraph 44 | ||
8170 | Reinstatement of the former position | ||
8125 | Change of the main classification |
Ipc: C07C 69/017 |
|
8128 | New person/name/address of the agent |
Representative=s name: ZUMSTEIN SEN., F., DR. ASSMANN, E., DIPL.-CHEM. DR |
|
8125 | Change of the main classification |
Ipc: C07F 9/12 |
|
8172 | Supplementary division/partition in: |
Ref country code: DE Ref document number: 2661085 Format of ref document f/p: P |
|
Q171 | Divided out to: |
Ref country code: DE Ref document number: 2661085 |
|
AH | Division in |
Ref country code: DE Ref document number: 2661085 Format of ref document f/p: P |
|
AH | Division in |
Ref country code: DE Ref document number: 2661085 Format of ref document f/p: P |
|
D2 | Grant after examination | ||
8364 | No opposition during term of opposition |